Acne Pipeline Yields Three Disappointments, One Win So Far In 2017

The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.

Allergan PLC and Paratek Pharmaceuticals Inc. had the only positive acne data out of four later-stage programs that have reported results so far in 2017 when the partners unveiled Phase III results for sarecycline, a potentially safer cycline oral antibiotic.

Allergan/Paratek, Xenon Pharmaceuticals Inc. and Foamix Pharmaceuticals Ltd. all reported acne clinical trial data in late March, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

06 Jun 2025

• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.